Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel ...

Summary by Post Register
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

1 Articles

Post RegisterPost Register
Center

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel ...

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Post Register broke the news in on Friday, August 15, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Idaho Falls icon

Idaho Falls

News
For You
SearchBlindspotLocal